Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Soaring cannabis stock primed and ready for a take-out

Investors were put on bid alert after it emerged the company had appointed Wall Street heavyweight Morgan Stanley to oversee the potential beauty parade.
Soaring cannabis stock primed and ready for a take-out
The interest comes as the company as it prepares to bring to market Epidiolex, a cannabis-derived medication to treat a severe form of childhood epilepsy.

Shares in GW Pharmaceuticals PLC (LON:GWP, NASDAQ:GWPH) were up almost 20% in afternoon trade amid reports the company has multiple potential suitors.

Investors were put on bid alert after it emerged the company had appointed Wall Street heavyweight Morgan Stanley to oversee the potential beauty parade.

The interest comes as the company as it prepares to bring to market Epidiolex, a cannabis-derived medication to treat a severe form of childhood epilepsy.

Analysts say the drug has the potential to deliver annual sales of around US$800mln.

According to Reuters, the financial news agency that broke the story, the identities of the potential GW Pharma suitors are unknown.

However it points out the big beasts in this sphere of the drugs market are Novartis (ETX:NOVN), Bayer (ETR:BAYN) and Almirall (BME:ALM).

However London broker Numis reckons Lundbeck (CPH:LUN), Otsuka (TYO:4578) and Biogen (NASDAQ:BIIB) might also be in the running.

Analyst  Paul Cuddon said: “With phase-three data on Epidiolex  (the key attraction)…due in the coming weeks and more data expected in December the timing is intriguing, allowing a potential acquirer an effective first option on the data.”

However he cautioned there are still “significant clinical, regulatory and commercial risks” associated with the treatment.

The shares, which are LSE and Nasdaq-quoted, were up 105p at 631.5p in a busy transatlantic trading session. That values the business at just shy of £2bn.

In the past six months the stock has advanced 178%, buoyed by some encouraging headline results from a phase III clinical trial of Epidiolex.

On the back of that the company was able to raise £190mln from US investors to bankroll the further development of its lead product.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use